News
-
-
-
PRESS RELEASE
enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year
enVVeno Medical Corporation reports progress towards FDA PMA approval for VenoValve and enVVe transcatheter-based valve replacement. Company ends quarter with $48.4M cash -
-
-
-
-
-
-